Nasdaq · CIK 0001213037
CRDF Cardiff Oncology, Inc.
Insider trading from SEC Form 4. Last filing Jul 16, 2026. Close $1.08 on Oct 9, 2026, +33% from the 52-week low and -66% from the high.
In brief
Cardiff Oncology, Inc. (CRDF) has 30 SEC Form 4 filings on file from 13 insiders, the latest filed on Jul 16, 2026. In the last 90 days insiders made 2 open-market buys worth $1.0M and 0 open-market sells worth $0, net +$1.0M.
8 open-market trades have been scored at CRDF. The newest: Mani Mohindru (Chief Executive Officer) bought $50k of stock on Jul 14, 2026, filed Jul 16, 2026, scored 63 (notable). The largest of the 8 shown: Gary W Pace (director) bought $1000k on Jul 14, 2026, scored 71 (notable). 2 insiders bought within 14 days of each other around Jul 14, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Cardiff Oncology, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 63Notable | Mani Mohindru Chief Executive Officer buy | $50k 34,364 shares | +139% | +11% from low-71% from high | |
| 71Notable | Gary W Pace director buy | $1000k 687,285 shares | +51% | +11% from low-71% from high | |
| 47Moderate | Gary W Pace director buy | $37k 30,000 shares | +2% | +3% from low-73% from high | |
| 64Notable | Mani Mohindru Chief Executive Officer buy | $30k 24,703 shares | - | +3% from low-73% from high | |
| 60Notable | Gary W Pace director buy | $711k 290,000 shares | +27% | +8% from low-53% from high | |
| 46Moderate | James E. Levine Chief Financial Officer buy | $37k 7,716 shares | +13% | - | |
| 46Moderate | Renee P Tannenbaum director buy | $34k 10,000 shares | +100% | - | |
| 64Notable | Gary W Pace director buy | $940k 361,615 shares | +52% | - |
Transactions
Every row filed, 36 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | Mani Mohindru Chief Executive Officer | POpen-market purchase Common Stock | +34,364 | $1.46 | $50k | 59,067 | Jul 16, 2026 |
| Jul 14, 2026 | Gary W Pace director | POpen-market purchase Common Stock | +687,285 | $1.46 | $1000k | 2,043,661 | Jul 16, 2026 |
| Jul 14, 2026 | Mani Mohindru Chief Executive Officer | POpen-market purchase Common Stock Purchase Warrantderivative | +34,364 | $0.00 | $0 | 34,364 | Jul 16, 2026 |
| Jul 14, 2026 | Gary W Pace director | POpen-market purchase Common Stock Purchase Warrantderivative | +687,285 | $0.00 | $0 | 687,285 | Jul 16, 2026 |
| Jun 18, 2026 | Gary W Pace director | POpen-market purchase Common Stock | +30,000 | $1.22 | $37k | 1,356,376 | Jun 22, 2026 |
| Jun 18, 2026 | Mani Mohindru Chief Executive Officer | POpen-market purchase Common Stock | +24,703 | $1.21 | $30k | 24,703 | Jun 22, 2026 |
| Jun 11, 2026 | James O Armitage director | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 228,104 | Jun 15, 2026 |
| Jun 11, 2026 | Gary W Pace director | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 228,104 | Jun 15, 2026 |
| Jun 11, 2026 | Rodney S Markin director | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 263,430 | Jun 15, 2026 |
| Jun 11, 2026 | Renee P Tannenbaum director | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 209,331 | Jun 15, 2026 |
| Jun 11, 2026 | Lale White director | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 199,246 | Jun 15, 2026 |
| Apr 27, 2026 | Ajay Aggarwal Chief Operating Officer | AGrant or award Stock Optionsderivative | +400,000 | $0.00 | $0 | 400,000 | Apr 28, 2026 |
| Apr 14, 2026 | Tod Smeal Chief Scientific Officer | AGrant or award Stock Optionsderivative | +300,000 | $0.00 | $0 | 1,279,805 | Apr 16, 2026 |
| Apr 6, 2026 | Joshua B Muntner Chief Financial Officer | AGrant or award Stock Optionsderivative | +486,650 | $0.00 | $0 | 487,150 | Apr 16, 2026 |
| Apr 6, 2026 | Joshua B Muntner Chief Financial Officer | AGrant or award Stock Optionsderivative | +486,650 | $0.00 | $0 | 487,150 | Apr 16, 2026 |
| Mar 31, 2026 | Mani Mohindru Chief Executive Officer | AGrant or award Stock Optionsderivative | +600,000 | $0.00 | $0 | 968,766 | Apr 2, 2026 |
| Feb 17, 2026 | Mani Mohindru Interim CEO | AGrant or award Stock Optionsderivative | +200,000 | $0.00 | $0 | 368,766 | Feb 18, 2026 |
| Feb 13, 2026 | Brigitte Ute Lindsay Chief Accounting Officer | AGrant or award Stock Optionsderivative | +200,000 | $0.00 | $0 | 1,025,334 | Feb 18, 2026 |
| Jul 30, 2025 | Gary W Pace director | POpen-market purchase Common Stock | +275,000 | $2.45 | $674k | 1,330,676 | Jul 31, 2025 |
| Jul 30, 2025 | Gary W Pace director | POpen-market purchase Common Stockindirect: By minor child | +15,000 | $2.45 | $37k | 1,345,676 | Jul 31, 2025 |
| Jun 26, 2025 | Mani Mohindru Chief Executive Officer | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 168,766 | Jun 30, 2025 |
| Jun 26, 2025 | Rodney S Markin director | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 222,865 | Jun 30, 2025 |
| Jun 26, 2025 | Renee P Tannenbaum director | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 168,766 | Jun 30, 2025 |
| Jun 26, 2025 | James O Armitage director | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 187,539 | Jun 27, 2025 |
| Jun 26, 2025 | Gary W Pace director | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 187,539 | Jun 27, 2025 |
| Jun 26, 2025 | Lale White director | AGrant or award Stock Optionsderivative | +40,565 | $0.00 | $0 | 158,681 | Jun 27, 2025 |
| Mar 11, 2025 | Tod Smeal Chief Scientific Officer | AGrant or award Stock Optionsderivative | +332,621 | $0.00 | $0 | 979,805 | Mar 13, 2025 |
| Mar 11, 2025 | Fairooz Kabbinavar Chief Medical Officer | AGrant or award Stock Optionsderivative | +150,000 | $0.00 | $0 | 780,008 | Mar 13, 2025 |
| Mar 11, 2025 | James E. Levine Chief Financial Officer | AGrant or award Stock Optionsderivative | +332,621 | $0.00 | $0 | 1,295,117 | Mar 13, 2025 |
| Mar 11, 2025 | Mark Erlander Chief Executive Officer | AGrant or award Stock Optionsderivative | +758,400 | $0.00 | $0 | 2,925,098 | Mar 13, 2025 |
| Dec 16, 2024 | James E. Levine Chief Financial Officer | POpen-market purchase Common Stockindirect: By Wife | +2,564 | $3.83 | $9,820 | 62,564 | Dec 18, 2024 |
| Dec 17, 2024 | James E. Levine Chief Financial Officer | POpen-market purchase Common Stockindirect: By Wife | +2,752 | $5.42 | $15k | 65,316 | Dec 18, 2024 |
| Dec 18, 2024 | James E. Levine Chief Financial Officer | POpen-market purchase Common Stockindirect: By Wife | +2,400 | $5.00 | $12k | 67,716 | Dec 18, 2024 |
| Dec 12, 2024 | Renee P Tannenbaum director | POpen-market purchase Common Stock | +10,000 | $3.42 | $34k | 20,000 | Dec 16, 2024 |
| Dec 11, 2024 | Gary W Pace director | POpen-market purchase Common Stock | +350,115 | $2.60 | $910k | 1,047,876 | Dec 12, 2024 |
| Dec 11, 2024 | Gary W Pace director | POpen-market purchase Common Stockindirect: By minor child | +11,500 | $2.60 | $30k | 1,059,376 | Dec 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Ajay AggarwalChief Operating Officer
- James O Armitagedirector
- Mark ErlanderChief Executive Officer
- Fairooz KabbinavarChief Medical Officer
- James E. LevineChief Financial Officer
- Brigitte Ute LindsayChief Accounting Officer
- Rodney S Markindirector
- Mani MohindruChief Executive Officer
- Joshua B MuntnerChief Financial Officer
- Gary W Pacedirector
- Tod SmealChief Scientific Officer
- Renee P Tannenbaumdirector
- Lale Whitedirector
Questions about CRDF
Answered from the filings on this page, as of the latest one.
Are insiders buying CRDF?
As of Jul 16, 2026, SEC Form 4 filings show 2 open-market buys worth $1.0M by 2 insiders and 0 open-market sells worth $0 by 0 insiders at Cardiff Oncology, Inc. in the last 90 days, net +$1.0M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade CRDF on the open market?
Mani Mohindru (Chief Executive Officer) bought $50k of CRDF on Jul 14, 2026 and filed the Form 4 on Jul 16, 2026. InsiderTell scored 63 (notable), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Cardiff Oncology, Inc.?
13 people have filed a Form 4 at Cardiff Oncology, Inc., among them Ajay Aggarwal (Chief Operating Officer), James O Armitage (director), Mark Erlander (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.